EN DE
Watch China Health Group Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

China Health Group Inc (8225) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of China Health Group Inc stock HK$0.13, price HK$0.06, upside +110.0%, quality 66 out of 100. Rating: strongly undervalued. Calculated from audited financials with 7 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China · ISIN KYG2117N1088

CH China Health Group Inc logo Thin data Nov 15, 2026

China Health Group Inc

8225 · HK

Cheap (52% below fair value) and solid company, but falling price: meets 2 of 3 rules.

Get notified free when this changes
Fair value HK$0.1260 · Strongly undervalued 
Quality 66/100 
Low debt 
Generates free cash flow 
Even on cautious assumptions the value is 60% above the price (HK$0.0960). 
Mixed Growth (revenue 5y −19.6 %/yr in CNY) 
Mixed vs. peers (6/11) 
Falling price (downtrend) 
Loss-making · -47.4% net margin (TTM) 
Narrow moat 10/100 · thin data
Thin data 
⚠ Thinly traded
Watch China Health Group Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$0.5200 HK$0.0600 Fair Value HK$0.1260 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

60‑month range HK$0.0600 – HK$0.5200 · fair‑value band HK$0.0960 – HK$0.1680 · the HK$0.0600 price screens below the HK$0.1260 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.

Follow China Health Group in your weekly email

Every Wednesday you see whether China Health Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

China Health Group Inc., together with its subsidiaries, researches and develops bio, natural, and synthetic drugs in the People's Republic of China.

Show moreShow less

It engages in the pharmacodynamics and clinical research of drugs; provision of post market and contracted pharmaceutical development services; and technological transfer and services for the research and development of drugs.

The company was formerly known as Venturepharm Laboratories Limited and changed its name to China Health Group Inc. in February 2015. China Health Group Inc. was founded in 1998 and is headquartered in Beijing, China.

Stock analysis

China Health Group Inc (8225) currently trades at HK$0.0600, while our model-based Fair Value estimate is HK$0.1260, implying the stock looks roughly 52% undervalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of HK$0.1850 per share, and 6 of the 7 models we run sit above the HK$0.0600 price.

Bear case: the Asset-Based group reads lowest at HK$0.0500, and 1 of the 7 models stay below the price. Data coverage for this calculation is low.

Scenario range: HK$0.0960 (bear) to HK$0.1680 (bull), the price of HK$0.0600 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 66/100 (solid quality), in the Healthcare sector.

Mixed Growth: Spin-off in 2014: revenue and profit before it include the divested business. Growth is measured afresh from 2014.

China Health Group Inc reported revenue of 27.8M CNY in FY2025 versus 83.6M CNY in FY2021, a compound −24.0%/yr. Reported net income was −14.6M CNY in FY2025.

Key figures

Market cap HK$59.7M (≈ $7.6M) Micro · P/S ratio 2.00 · Net margin −52.4% · Return on equity −19.9% · Return on assets (EBIT) −13.4% (5-year average) · Operating margin −47.5% · Revenue (TTM) 29.9M CNY · Revenue growth (YoY) +6.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 62% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −10% fair-value upside, at 110%, 8225 screens cheaper than that median.

Fair Value models

Bear HK$0.0960 Fair Value HK$0.1260 Bull HK$0.1680
Price HK$0.0600 · Upside +110.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF HK$0.1400 HK$0.2200 HK$0.3300 77
Growth DCF HK$0.1400 HK$0.2100 HK$0.3100 76
5Y Revenue Exit HK$0.1100 HK$0.1600 HK$0.2200 71
All 7 models by family
DCF Models
FCF DCF HK$0.1400 HK$0.2200 HK$0.3300 77
5Y Revenue Exit HK$0.1100 HK$0.1600 HK$0.2200 71
10Y Revenue Exit HK$0.1200 HK$0.1700 HK$0.2400 65
Multiples
EV/Revenue HK$0.1000 HK$0.1300 HK$0.1600 54
Asset-Based
NCAV (Graham) HK$0.0300 HK$0.0500 HK$0.0600 54
Growth DCF
Growth DCF HK$0.1400 HK$0.2100 HK$0.3100 76
Rev-Margin DCF HK$0.1100 HK$0.1600 HK$0.2200 71

Open the full fair value analysis →

Quality Score breakdown

Overall quality 66/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 10
How much profit the company makes from its sales and capital
Quality Growth 65
Are margins and returns getting better?
Cashflow 100
Do the profits arrive as real cash?
Financial strength 71
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 69
How calm the share price moves, does not count
Price momentum 6
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Spin-off in 2014: revenue and profit before it include the divested business. Growth is measured afresh from 2014.
Revenue growth 1 year
+5.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+28.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−19.6%
Start year 2020 (pandemic). Over 10 years: +3.1% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
66.7% (2020) → −51.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−21.9%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −23.2% a year for the price.

Watch 8225, get fair value alerts →

Compare China Health Group Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 150 stocks

Beats the industry median on 6/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 66 · Top 25%
Fair Value upside +110.0% · Top 25%
Profitability
Return on assets −16.7% · Bottom 25%
Net margin (12 months) −47.4% · Bottom 25%
Operating margin (12 months) −47.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 6.2% · Below median
Balance sheet
Debt / equity 0.09× · Below median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 0.92× · Cheapest 25%
P/S (12 months) 1.70× · Cheapest 25%
Price / free cash flow (fiscal year) 5.6× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 12
FUTURE (revenue growth)31 · sector 35
PAST (return on equity)0 · sector 8
HEALTH (low debt)96 · sector 95
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
WuXi AppTec Co 603259 ¥146.30 ¥164.66 +13% vs 8225
IQVIA Holdings IQV $265.12 $291.63 +10% vs 8225
Illumina, Inc ILMN $207.01 $227.71 +10% vs 8225
Thermo Fisher Scientific Inc TMO $700.22 $686.04 −2% vs 8225
Danaher Corporation DHR $233.02 $209.18 −10% vs 8225
IDEXX Laboratories, Inc IDXX $704.23 $496.48 −30% vs 8225
Lonza Group LONN CHF 666.00 CHF 259.80 −61% vs 8225
Mettler-Toledo International Inc MTD $1,739 $655.06 −62% vs 8225
Agilent Technologies, Inc A $173.96 $64.53 −63% vs 8225
Waters Corporation WAT $460.25 $91.26 −80% vs 8225

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

China Health Group Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "China Health Group Inc Fair Value". https://www.fairvalue-calculator.com/stock/8225

Frequently asked questions

Is China Health Group Inc (8225) overvalued or undervalued?
As of Nov 15, 2026, our model estimates a fair value of HK$0.1260 versus a price of HK$0.0600, about +110% upside (undervalued).
What is the fair value of 8225?
Our model-based fair value for China Health Group Inc is HK$0.1260 (as of Nov 15, 2026), built from audited fundamentals. The current price: HK$0.0600.
What is the quality score of 8225?
China Health Group Inc has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for China Health Group Inc (8225)?
Our model-based price target is the fair value of HK$0.1260 (as of Nov 15, 2026) from 7 valuation models. Cautious scenario HK$0.0960, optimistic scenario HK$0.1680. It is a calculation from audited fundamentals, not an analyst target.
What is the China Health Group Inc stock forecast for 2026?
Our models put fair value at HK$0.1260, about +110% upside versus a price of HK$0.0600 (undervalued). Cautious scenario HK$0.0960, optimistic scenario HK$0.1680. The calculation is refreshed regularly with new filings.
What is the revenue of China Health Group Inc (8225)?
China Health Group Inc reported trailing-twelve-month revenue of about 29.9M CNY (latest available figure, as of Nov 15, 2026).
What growth is priced into China Health Group Inc (8225)?
Today's price is already fair in a discounted-cash-flow model if free cash flow at China Health Group Inc shrinks by 21.9 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue fell 19.7 % per year. As of Nov 15, 2026.
What discount rate (WACC) does the fair value of 8225 use?
Our models discount China Health Group Inc at 10.3 %: a base by market capitalisation (nano), country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For China Health Group Inc that is -21.9 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has China Health Group Inc (8225) delivered so far?
Over the past 5 years revenue at China Health Group Inc shrank 19.7 % a year. The price currently implies free-cash-flow growth of -21.9 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of China Health Group Inc (8225) growing?
The median revenue growth in the sector is +5.9 % a year. That is the yardstick for the growth priced into China Health Group Inc (-21.9 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of China Health Group Inc (8225)?
The free-cash-flow yield on the price is 17.78 %: that much free cash flow China Health Group Inc produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of China Health Group Inc (8225)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For China Health Group Inc it is HK$0.1260 per share (as of Nov 15, 2026), against a price of HK$0.0600. It is the blended result of 7 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is China Health Group Inc stock overvalued or undervalued in 2026?
As of Nov 15, 2026, 8225 trades below its calculated fair value: price HK$0.0600, fair value HK$0.1260, a gap of about +110% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 8225?
No. The price is what the market pays today (HK$0.0600); the fair value is what the company's own numbers justify (HK$0.1260). For China Health Group Inc the two are HK$0.0660 per share apart. That gap is exactly why we show both numbers side by side.
How much is China Health Group Inc worth?
The market values China Health Group Inc at about HK$59.7M (market capitalisation, as of Nov 15, 2026). Per share that is HK$0.0600; our models calculate a fair value of HK$0.1260 per share.
What do the bullish and bearish scenarios say about 8225?
Our models span a range for China Health Group Inc: cautious scenario HK$0.0960, base HK$0.1260, optimistic HK$0.1680 per share (as of Nov 15, 2026, price HK$0.0600). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of China Health Group Inc (8225)?
Balance-sheet figures for China Health Group Inc (as of Nov 15, 2026): return on equity −19.9%, debt of 0.09 per unit of equity. They feed the Quality Score of 66/100, which measures business quality independently of the share price.
How far is 8225 from its 52-week high?
China Health Group Inc trades at HK$0.0600, about 62% below its 52-week high of HK$0.1560 and at the low of HK$0.0600 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.1260 is for.
Which stocks are comparable to China Health Group Inc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, IDEXX Laboratories, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is China Health Group Inc stock attractive at the current price?
The data as of Nov 15, 2026: price HK$0.0600, calculated fair value HK$0.1260 (+110%), Quality Score 66/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 8225 calculated?
We run China Health Group Inc through 7 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of HK$0.1260 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. China Health Group Inc currently trades 52% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of China Health Group Inc (8225)?
The closing price on Nov 13, 2026 was HK$0.0600. Our model-based fair value is HK$0.1260, about +110% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with China Health Group Inc right now?
The price is below even our cautious bear case (HK$0.0960). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (66/100) at a price below fair value, the discount is the argument here, not the business quality.

Key figures of China Health Group Inc

How large is the market capitalisation of China Health Group Inc (8225)?
The market capitalisation of China Health Group Inc is HK$59.7M (≈ $7.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of China Health Group Inc (8225)?
The price-to-sales ratio of China Health Group Inc is 2.00 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of China Health Group Inc (8225)?
The net margin of China Health Group Inc is −52.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of China Health Group Inc (8225)?
The return on equity (ROE) of China Health Group Inc is −19.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of China Health Group Inc (8225)?
On an EBIT basis the return on assets of China Health Group Inc is −13.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of China Health Group Inc (8225)?
The operating margin of China Health Group Inc is −47.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at China Health Group Inc (8225)?
Revenue at China Health Group Inc is growing 6.2% versus a year earlier (3y avg +28.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at China Health Group Inc (8225)?
Earnings per share at China Health Group Inc are growing 9.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does China Health Group Inc (8225) hold?
China Health Group Inc holds more cash than debt, 23.4M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch China Health Group Inc in the live analysis

One click puts China Health Group Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.